ResearcherUniversity of ChicagoActive in the last 2 years

Mark Mimee

ORCID-verified (high confidence)As of 10 November 2026

Matched on ORCID iD 0000-0002-3083-2671; OpenAlex author ID A5005478480; NIH RePORTER profile ID 16167504.

Their work

Papers: 1 (first author 0, last author 1)
Trials: 0
Grants: 1
Collaborators: 2

Papers, trials and grants by year

2026: 1 paper, 1 grant

Papers 1

Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. Last author DOI 10.1126/sciadv.adz1388 ↗

Grants 1

Genetically-engineered Bacteria Overcome Therapy Resistance R01CA292860 ↗

Closest collaborators

The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.

Ralph R. Weichselbaum · 1 shared paper, 1 shared grant, 2026
- Grant Genetically-engineered Bacteria Overcome Therapy Resistance R01CA292860 ↗
- Paper Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. DOI 10.1126/sciadv.adz1388 ↗
Jaehyun Lee · 1 shared paper, 2026
- Paper Engineered probiotic Bifidobacterium for tumor-targeted pancreatic cancer therapy. DOI 10.1126/sciadv.adz1388 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.